Flammiger et al. (57) reported that Prostate-specific antigen recurrence‐free survival was lower in patients with higher densities of FOXP3+ regulatory T cells, and that high levels of FOXP3+ regulatory T cells were associated with advanced prostate cancer tumor stage. This evidence concerns the gene FOXP3 and neoplasm.